NewSquare Capital’s Corcept Therapeutics CORT Stock Holding History

NewSquare Capital’s Portfolio CORT Stock Details CORT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-116	Closed	-$2.36K	–	901
2022 Q4	$2.36K	Hold	116	–	–	﹤0.01%	464
2022 Q3	$3K	Hold	116	–	–	﹤0.01%	323
2022 Q2	$3K	Hold	116	–	–	﹤0.01%	303
2022 Q1	$3K	Buy	+116	New	+$2.47K	﹤0.01%	323

Other funds holding CORT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ISL

Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return

NHAS

Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

NewSquare Capital's CORT Position: Q1 2023 in Review

NewSquare Capital sold out of Corcept Therapeutics (CORT) in Q1 2023, closing a stake of 116 shares — an estimated $2.36K sold.

NewSquare Capital first reported a position in CORT in Q1 2022 and held it in 4 quarters. The position peaked at $3K in Q3 2022. 232 funds tracked by Wall St. Rank hold CORT as of Q1 2023.

NewSquare Capital reported no remaining Corcept Therapeutics position as of Q1 2023 after selling out during the quarter.
NewSquare Capital sold 116 Corcept Therapeutics shares in Q1 2023, an estimated $2.36K.
NewSquare Capital first reported a position in Corcept Therapeutics in Q1 2022 and held it in 4 quarters.
NewSquare Capital's Corcept Therapeutics position peaked at $3K in Q3 2022.
232 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2023.

Based on NewSquare Capital's 13F filing for Q1 2023, filed 1 May 2023.